Company Update (NASDAQ:KPTI): Karyopharm Therapeutics Inc to Present Clinical Data Update for Selinexor (KPT-330) in Hematologic Malignancies
Karyopharm Therapeutics Inc (NASDAQ:KPTI) announced the presentation of clinical data for its lead drug candidate, selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound, during a Karyopharm-sponsored event with webcast scheduled for Monday, December 7, 2015from 8:30 – 9:30 p.m. ET, immediately following formal programming for the 57thAmerican Society of Hematology (ASH) Annual Meeting. The event, entitled “Broadening the Foundation for SINE-Based Therapy in Oncology: ASH 2015,” will include presentations by selinexor clinical investigators and Karyopharm management describing new clinical data, including data related to selinexor’s activity in combination with other active agents in multiple myeloma and acute myeloid leukemia, followed by a Q&A session. (Original Source)
Shares of Karyopharm Therapeutics closed today at $18.70, down $0.28 or -1.48%. KPTI has a 1-year high of $49.01 and a 1-year low of $10. The stock’s 50-day moving average is $14.89 and its 200-day moving average is $18.95.
On the ratings front, Karyopharm has been the subject of a number of recent research reports. In a report issued on November 9, J.P. Morgan analyst Whitney Ijem maintained a Buy rating on KPTI, with a price target of $20, which represents a potential upside of 7.0% from where the stock is currently trading. Separately, on August 12, FBR’s Arlinda Lee reiterated a Buy rating on the stock and has a price target of $42.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Whitney Ijem and Arlinda Lee have a total average return of 36.2% and -18.6% respectively. Ijem has a success rate of 100.0% and is ranked #1046 out of 3649 analysts, while Lee has a success rate of 30.6% and is ranked #3610.
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and subsequent commercialization of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.